These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 28219375)

  • 21. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.
    Weber J
    Semin Oncol; 2010 Oct; 37(5):430-9. PubMed ID: 21074057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibodies in oncology.
    Pillay V; Gan HK; Scott AM
    N Biotechnol; 2011 Sep; 28(5):518-29. PubMed ID: 21473941
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Anti-cancer monoclonal antibody].
    Sasaki S; Ishida T; Tsujisaki M; Imai K
    Nihon Rinsho; 2005 Apr; 63 Suppl 4():608-12. PubMed ID: 15861718
    [No Abstract]   [Full Text] [Related]  

  • 24. Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors.
    Di Fede G; Bronte G; Rizzo S; Rolfo Cervetto C; Cocorullo G; Gulotta G; Bazan V; Russo A
    Expert Opin Biol Ther; 2011 Nov; 11(11):1433-45. PubMed ID: 21663530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plant-Produced Monoclonal Antibody as Immunotherapy for Cancer.
    Nessa MU; Rahman MA; Kabir Y
    Biomed Res Int; 2020; 2020():3038564. PubMed ID: 32908881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New antibody approaches to lymphoma therapy.
    Suresh T; Lee LX; Joshi J; Barta SK
    J Hematol Oncol; 2014 Sep; 7():58. PubMed ID: 25355407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
    Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
    Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review).
    Oei AL; Sweep FC; Thomas CM; Boerman OC; Massuger LF
    Int J Oncol; 2008 Jun; 32(6):1145-57. PubMed ID: 18497976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New insight into cancer immunotherapy.
    Escribese MM; Barber D
    Allergol Immunopathol (Madr); 2017 Dec; 45 Suppl 1():50-55. PubMed ID: 29108766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines.
    Yip YL; Ward RL
    Cancer Immunol Immunother; 2002 Jan; 50(11):569-87. PubMed ID: 11807621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic monoclonal antibodies in ophthalmology.
    Rodrigues EB; Farah ME; Maia M; Penha FM; Regatieri C; Melo GB; Pinheiro MM; Zanetti CR
    Prog Retin Eye Res; 2009 Mar; 28(2):117-44. PubMed ID: 19114125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nature's best weapons to fight cancer. Revival of human monoclonal IgM antibodies.
    Vollmers HP; Brändlein S
    Hum Antibodies; 2002; 11(4):131-42. PubMed ID: 12775893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapeutic approaches for cancer therapy: An updated review.
    Kazemi T; Younesi V; Jadidi-Niaragh F; Yousefi M
    Artif Cells Nanomed Biotechnol; 2016 May; 44(3):769-79. PubMed ID: 25801036
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy.
    Adachi K; Tamada K
    Cancer Sci; 2015 Aug; 106(8):945-50. PubMed ID: 25981182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel tumor antigen-specific monoclonal antibody-based immunotherapy to eradicate both differentiated cancer cells and cancer-initiating cells in solid tumors.
    Sabbatino F; Wang Y; Wang X; Schwab JH; Ferrone S; Ferrone CR
    Semin Oncol; 2014 Oct; 41(5):685-99. PubMed ID: 25440613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The translational potential for target validation and therapy using intracellular antibodies in oncology.
    Weidle UH; Maisel D; Brinkmann U; Tiefenthaler G
    Cancer Genomics Proteomics; 2013; 10(6):239-50. PubMed ID: 24336633
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Challenges in monoclonal antibody-based therapies.
    Samaranayake H; Wirth T; Schenkwein D; Räty JK; Ylä-Herttuala S
    Ann Med; 2009; 41(5):322-31. PubMed ID: 19234897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Using monoclonal antibodies to stimulate antitumor cellular immunity.
    Durrant LG; Pudney VA; Spendlove I
    Expert Rev Vaccines; 2011 Jul; 10(7):1093-106. PubMed ID: 21806402
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Challenges and opportunities for monoclonal antibody therapy in veterinary oncology.
    Beirão BC; Raposo T; Jain S; Hupp T; Argyle DJ
    Vet J; 2016 Dec; 218():40-50. PubMed ID: 27938708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-Lymphoma Monoclonal Antibodies: Making Better Antibodies and Making Antibodies Better.
    Weiner GJ
    Trans Am Clin Climatol Assoc; 2015; 126():87-92. PubMed ID: 26330662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.